Since 2011, several novel first-line unresectable or metastatic malignant melanoma therapies have gained approval in the U.S. and in Europe. These agents, namely immunotherapies and BRAF and MEK inhibitors, have revolutionized the treatment landscape of malignant melanoma, considerably improving patients’ survival. Despite the remarkable improvement in survival, the prevailing unmet needs in first-line unresectable or metastatic malignant melanoma therapies still consolidate around the improvements in efficacy, creating a significant clinical and commercial opportunity for drug developers to exploit with new therapies which can extend patients lives.

Table of contents

  • Malignant Melanoma - Unmet Need - Detailed, Expanded Analysis: First-Line Unresectable Or Metastatic Melanoma
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in First-line Unresectable or Metastatic Malignant Melanoma
        • Importance of Efficacy Attributes to Prescribing Decisions in First-Line Unresectable or Metastatic Malignant Melanoma — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in First-Line Unresectable or Metastatic Malignant Melanoma — Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in First-Line Unresectable or Metastatic Malignant Melanoma — United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in First-Line Unresectable or Metastatic Malignant Melanoma — Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in First-Line Unresectable or Metastatic Malignant Melanoma — United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in First-Line Unresectable or Metastatic Malignant Melanoma — Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration and Non-Clinical Attributes to Prescribing Decisions in First-Line Unresectable or Metastatic Malignant Melanoma — United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration and Non-Clinical Attributes to Prescribing Decisions in First-Line Unresectable or Metastatic Malignant Melanoma — Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Therapies for First-Line Unresectable or Metastatic Malignant Melanoma
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for First-Line Unresectable or Metastatic Malignant Melanoma — United States
        • Overall Performance of Key Therapies for First-Line Unresectable or Metastatic Malignant Melanoma — Europe
        • Relative Performance of Key Therapies for First-Line Unresectable or Metastatic Malignant Melanoma Across Select Efficacy Attributes — United States
        • Relative Performance of Key Therapies for First-Line Unresectable or Metastatic Malignant Melanoma Across Select Efficacy Attributes — Europe
        • Relative Performance of Key Therapies for First-Line Unresectable or Metastatic Malignant Melanoma Across Select Safety and Tolerability Attributes — United States
        • Relative Performance of Key Therapies for First-line Unresectable or Metastatic Malignant Melanoma Across Select Safety and Tolerability Attributes — Europe
        • Relative Performance of Key Therapies for First-Line Unresectable or Metastatic Malignant Melanoma Across Select Convenience of Administration Attributes — United States
        • Relative Performance of Key Therapies for First-Line Unresectable or Metastatic Malignant Melanoma Across Select Convenience of Administration Attributes — Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Medical Oncologists' Satisfaction With the Performance of Key Therapies for First-Line Unresectable or Metastatic Malignant Melanoma on Efficacy, Safety and Tolerability, Convenience of Administration and Non-Clinical Factors — United States
        • Surveyed Medical Oncologists' Satisfaction With the Performance of Key Therapies for First-Line Unresectable or Metastatic Malignant Melanoma on Efficacy, Safety and Tolerability, Convenience of Administration and Non-Clinical Factors — Europe
      • Physician Rating of Unmet Need in First-line Unresectable or Metastatic Malignant Melanoma
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in First-Line Unresectable or Metastatic Malignant Melanoma — United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in First-Line Unresectable or Metastatic Malignant Melanoma — Europe
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in First-Line Unresectable or Metastatic Malignant Melanoma — United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in First-Line Unresectable or Metastatic Malignant Melanoma — Europe
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in First-Line Unresectable or Metastatic Malignant Melanoma — United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in First-Line Unresectable or Metastatic Malignant Melanoma — Europe
      • Unmet Need in First-line Unresectable or Metastatic Malignant Melanoma and Related Indications
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need in First-Line Unresectable or Metastatic Malignant Melanoma and Related Indications — United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need in First-Line Unresectable or Metastatic Malignant Melanoma and Related Indications — Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Malignant Melanoma Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent with a Substantial Survival Benefit
        • Opportunity: A New Agent That Elicits Better Responses
        • Opportunity: A New Agent That Elicits More Durable Responses
        • Opportunity: A Novel Therapy with a Lower Incidence of Immune-Related Adverse Events Compared to PD-1 Inhibitors (Keytruda and Opdivo)
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
        • Assigned Prohibitions for the Conjoint Module
      • Attribute Importance and Part-Worth Utilities
        • First-Line Unresectable or Metastatic Malignant Melanoma Target Product Profile: Attribute Importance
        • First-Line Unresectable or Metastatic Malignant Melanoma Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • First-Line Unresectable or Metastatic Malignant Melanoma Market Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • First-Line Unresectable or Metastatic Malignant Melanoma Market Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • First-Line Unresectable or Metastatic Malignant Melanoma Market Market Simulations: Target Product Profiles Included in Scenario 1
        • First-Line Unresectable or Metastatic Malignant Melanoma Market Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • First-Line Unresectable or Metastatic Malignant Melanoma Market Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • First-Line Unresectable or Metastatic Malignant Melanoma Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Michalina Jenkins, MSc, PhD

Michalina Jenkins, M.Sc., Ph.D., is a business insights analyst in the oncology team at Decision Resources Group. She is a specialist in malignant melanoma and has expertise in prostate cancer.

Dr. Jenkins obtained her doctorate in molecular biology of cancer from University of London, where she focused on investigating the impact of phosphoinositide 3-kinases (PI3Ks) signaling on cancer cell biology. Dr. Jenkins holds a M.Sc. in pharmacology from the University of Oxford and a B.Sc. in biotechnology from Oxford Brookes University. Dr. Jenkins worked as a research assistant at Oxford Gene Technology where she was involved in microarray gene expression analysis and R&D projects developing novel gene expression analysis platforms.


Related Reports

Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/ME...

View Details

Malignant Melanoma | Disease Landscape and Forecast | G7 | 2020

The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche /...

View Details

Malignant Melanoma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of ma...

View Details

Malignant Melanoma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key endometrial cancer pati...

View Details